Cyclandelate in the Treatment of Cerebral Arteriosclerosis*
作者:
PETER HALL,
期刊:
Journal of the American Geriatrics Society
(WILEY Available online 1976)
卷期:
Volume 24,
issue 1
页码: 41-45
ISSN:0002-8614
年代: 1976
DOI:10.1111/j.1532-5415.1976.tb03253.x
出版商: Blackwell Publishing Ltd
数据来源: WILEY
摘要:
ABSTRACT:Twenty‐one patients with cerebral arteriosclerosis were treated for twelve months with placebo or cyclandelate (Cyclospasmol), 400 mg four times daily, in a double‐blind study with medication cross‐over after six months. The group included 8 men and 13 women, with a mean age of 69 years. Each patient showed at least 5 of 9 signs or symptoms adopted as “inclusion criteria” for the study. Concomitant psychotropic or other drug therapy was standardized or matched during the trial, and periodic assessments were made of the patients' behavioral, physical, neurologic and psychiatric status. No serious side effects were observed. There was no significant difference between the cyclandelate and placebo phases in measurements of physical state. Changes on the gross behavior scales were insufficient for analysis. Tests of memory, control of manual dexterity and comprehension of everyday situations showed statistically significant improvement during the cyclandelate phase. In contrast to placebo, no measurable intellectual decline occurred during cyclandelat
点击下载:
PDF
(851KB)
返 回